Skip to main content

Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas.

Publication ,  Journal Article
Kumaki, F; Kawai, T; Churg, A; Galateau-Sallé, FB; Hasleton, P; Henderson, D; Roggli, V; Travis, WD; Cagle, PT; Ferrans, VJ
Published in: Am J Surg Pathol
March 2002

To evaluate the usefulness of determinations of telomerase activity for distinguishing malignant from benign mesothelial lesions, immunohistochemical (using a rabbit polyclonal antibody and the peroxidase method; n = 68) and in situ hybridization (using sense and antisense oligonucleotide probes; n = 46) studies were made on malignant mesotheliomas (epithelioid, 39; sarcomatoid, 18, including 2 of the desmoplastic type; and biphasic, 11) and 19 benign mesothelial lesions (benign mesothelial hyperplasia, 3; and reactive pleuritis, 16). In addition, biochemical studies of telomerase activity were made in 9 of the malignant mesotheliomas. Telomerase activity was detected histochemically in all but one of the malignant mesotheliomas, but only in one (pleuritis) of the benign lesions, in which it was present only in activated lymphocytes. Antisense hybridization signals indicated the presence of telomerase mRNA mainly in the cytoplasm of the malignant cells. Sense probes gave negative results. Biochemical determinations revealed a strong telomerase activity in the 9 malignant mesotheliomas examined. This study demonstrates the usefulness of immunohistochemical staining for the evaluation of mesotheliomas. The required immunostaining can be performed using paraffin sections of formalin-fixed tissues.

Duke Scholars

Published In

Am J Surg Pathol

DOI

ISSN

0147-5185

Publication Date

March 2002

Volume

26

Issue

3

Start / End Page

365 / 370

Location

United States

Related Subject Headings

  • Telomerase
  • Pathology
  • Mesothelioma
  • In Situ Hybridization
  • Immunohistochemistry
  • Humans
  • Histocytochemistry
  • DNA-Binding Proteins
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kumaki, F., Kawai, T., Churg, A., Galateau-Sallé, F. B., Hasleton, P., Henderson, D., … Ferrans, V. J. (2002). Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol, 26(3), 365–370. https://doi.org/10.1097/00000478-200203000-00011
Kumaki, Fumiyuki, Toshiaki Kawai, Andrew Churg, Françoise B. Galateau-Sallé, Philip Hasleton, Douglas Henderson, Victor Roggli, William D. Travis, Philip T. Cagle, and Victor J. Ferrans. “Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas.Am J Surg Pathol 26, no. 3 (March 2002): 365–70. https://doi.org/10.1097/00000478-200203000-00011.
Kumaki F, Kawai T, Churg A, Galateau-Sallé FB, Hasleton P, Henderson D, et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol. 2002 Mar;26(3):365–70.
Kumaki, Fumiyuki, et al. “Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas.Am J Surg Pathol, vol. 26, no. 3, Mar. 2002, pp. 365–70. Pubmed, doi:10.1097/00000478-200203000-00011.
Kumaki F, Kawai T, Churg A, Galateau-Sallé FB, Hasleton P, Henderson D, Roggli V, Travis WD, Cagle PT, Ferrans VJ. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol. 2002 Mar;26(3):365–370.

Published In

Am J Surg Pathol

DOI

ISSN

0147-5185

Publication Date

March 2002

Volume

26

Issue

3

Start / End Page

365 / 370

Location

United States

Related Subject Headings

  • Telomerase
  • Pathology
  • Mesothelioma
  • In Situ Hybridization
  • Immunohistochemistry
  • Humans
  • Histocytochemistry
  • DNA-Binding Proteins
  • 3202 Clinical sciences
  • 1103 Clinical Sciences